<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03519243</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-131-2</org_study_id>
    <nct_id>NCT03519243</nct_id>
  </id_info>
  <brief_title>Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis</brief_title>
  <official_title>An International Multicenter Randomized Open-Label Comparative Study of the Efficacy and Safety of BCD-131 (JSC BIOCAD, Russia) and Mircera (F. Hoffmann-La Roche Ltd, Switzerland) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BCD-131 is pegylated darbepoetin beta. BCD-131-2 is International Multicenter Randomized
      Open-Label Comparative Study (Phase II) of the Efficacy and Safety of BCD-131 (JSC BIOCAD,
      Russia) and Mircera (F. Hoffmann-La Roche Ltd, Switzerland) in Treatment of Anemia in Chronic
      Kidney Disease Patients on Dialysis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period</measure>
    <time_frame>Baseline - measurements on Screening (weeks -4 - 0) and on day 1; Evaluation period - weekly measures on weeks 21 to 23</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who developed AEs/SAEs that, in the Investigator's opinion, are related to BCD-131</measure>
    <time_frame>Week 23</time_frame>
    <description>the proportion of patients, in each group, who developed СТСАЕ v. 4.03 Grade 3-4 AEs that, in the Investigator's opinion, are related to BCD-131
the proportion of patients, in each group, who discontinued the study due to AEs/SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of BAb- and NAb-positive patients</measure>
    <time_frame>Week 9, 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-672 hour)</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-∞)</measure>
    <time_frame>day 28, weeks 5, 9, 13, 17, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>day 28, weeks 5, 9, 13, 17, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC(0-672 hour)</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AC-Emax</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>BCD-131 1,05 mcg/kg * conversion ratio</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneously monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131 1,7 mcg/kg * conversion ratio</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneously monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131 2,75 mcg/kg * conversion ratio</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneously monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mircera</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneously monthly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-131</intervention_name>
    <description>subcutaneously monthly</description>
    <arm_group_label>BCD-131 1,05 mcg/kg * conversion ratio</arm_group_label>
    <arm_group_label>BCD-131 1,7 mcg/kg * conversion ratio</arm_group_label>
    <arm_group_label>BCD-131 2,75 mcg/kg * conversion ratio</arm_group_label>
    <other_name>pegylated darbepoetin beta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mircera</intervention_name>
    <description>subcutaneously monthly</description>
    <arm_group_label>Mircera</arm_group_label>
    <other_name>Methoxy polyethylene glycol-epoetin beta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent to participate in the study.

          -  Men and women aged from 18 to 75 years (inclusive) on the day of signing informed
             consent;

          -  End-stage kidney disease.

          -  Need for dialysis for at least 3 months before signing informed consent.

          -  Need for at least 12 hours on standard dialysis procedure weekly.

          -  rHuEpo (epoetin alpha, epoetin beta, darbepoetin alpha) administration for at least 3
             months before signing informed consent.

          -  Regular rHuEpo (epoetin alfa, epoetin beta, darbepoetin alfa) administration 1, 2 or 3
             times a week (stable dose, stable frequency) before signing informed consent.

          -  Target hemoglobin level (100-120 g/l) for at least 3 months before signing informed
             consent.

          -  Effective dialysis dose index (Kt/v) ≥1.2 for patients receiving hemodialysis and
             (Kt/v) ≥1.7 for patients receiving peritoneal dialysis.

          -  TSAT ≥20%, Serum ferritin &gt;200 ng/ml.

          -  Patients and their sexual partners with childbearing potential must implement reliable
             contraceptive measures during all the study treatment, starting 4 weeks prior to the
             administration of the first dose of investigational product until 4 weeks after the
             last dose of investigational product. This requirement does not apply to participants
             who have undergone surgical sterilization. Reliable contraceptive measures include two
             methods of contraception, including one barrier method/

          -  Patients should be able to follow the Protocol procedures

        Exclusion Criteria:

          -  Any other causes of anemia except for renal anemia, including folate and B12
             deficiency, chronic blood loss, aluminium intoxication, sickle-cell anemia, chronic
             disease anemia (CRP above 20 mg/l), refractory anemia with blast cells in peripheral
             blood.

          -  Lupus nephritis of kidney disease due to systemic vasculitis.

          -  Platelet count below 100х10^9 cells/l.

          -  Scheduled kidney transplant during study participation period.

          -  Hypersensitivity to darbepoetin alfa or of any components of study drugs, or to Fe
             (III)-hydroxide-sucrose complex.

          -  Vaccination less than 8 weeks before signing informed consent.

          -  Liver cirrhosis with portal hypertension and/or splenomegaly and/or ascitis.

          -  HIV infection, active HBV, HCV.

          -  ALT, AST level above 3x ULN.

          -  Congestive heart failure (Grade IV NYHA)

          -  Resistant arterial hypertension.

          -  Unstable angina.

          -  Hemoglobinopathy, MDS, hematologic malignancy, PRCA.

          -  Severe secondary hyperparathyroidism.

          -  Gastrointestinal bleeding history.

          -  Thrombotic events history (myocardial infarction, stroke, TIA, DVT, PATE) less than 6
             months before signing informed consent.

          -  Seizures, including epilepsy.

          -  Major surgery in less than 1 month before signing informed consent

          -  Blood transfusions in less than 3 months before signing informed consent.

          -  Acute inflammatory diseases or exacerbations of chronic inflammation.

          -  Severe psychiatric disorders and suicidal ideation and suicidal behavior.

          -  History of malignancy, excluding appropriately treated basal cell carcinoma or
             cervical carcinoma in situ.

          -  Alcohol or drug abuse.

          -  Simultaneous participation in other trials or in less than 3 months before signing
             informed consent

          -  Pregnancy of breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Ivanov, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>JCS BIOCAD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City Clinical Hospital №9</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleg Kalachik</last_name>
      <phone>+375 (17) 272-73-90</phone>
      <email>m9gkb@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Mariin Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viktor Suchkov</last_name>
      <phone>+7 (812) 275-74-46</phone>
      <email>b16@zdrav.spb.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>B.Braun Avitum Russland Clinics Ltd.</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anastasia Sabodash, PhD</last_name>
      <phone>+7 (812) 640-13-04</phone>
      <email>clinicsavitum.ru@bbraun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

